New Lawsuit Says Makers of Diabetes Drug Farxiga Hid Risks of Ketoacidosis, Kidney Damage

CORPUS CHRISTI, Texas — In a newly filed lawsuit, a Texas woman has accused the makers of Type 2 diabetes drug Farxiga of failing to warn consumers and doctors that it carries a high risk of diabetic ketoacidosis and kidney damage.

According to the May 23 complaint filed in the U.S. District Court for the Southern District of Texas, defendants knew of the significant risks posed by Farxiga, but concealed those risks while promoting the drug in nationwide sales and marketing campaigns.

Farxiga (dapagliflozin), a sodium glucose cotransporter 2 inhibitor developed and manufactured by Bristol-Myers Squibb Co. and AstraZeneca, was …